<DOC>
	<DOCNO>NCT00765817</DOCNO>
	<brief_summary>This study compare efficacy safety exenatide versus placebo adult whose diabetes fully control insulin glargine without metformin and/or pioglitazone .</brief_summary>
	<brief_title>Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have type 2 diabetes . Have take insulin glargine dose ≥20 units/day least 3 month enter study . Have take insulin glargine alone combination one follow least 3 month enter study : 1. metformin ( stable dose 6 week ) 2. pioglitazone ( stable dose 6 week ) 3. combination metformin pioglitazone ( stable dose 6 week ) Have HbA1C 7.1 % 10.5 % , inclusive . Have body mass index ( BMI ) ≤45 kg/m2 . Have history stable body weight ( vary &gt; 5 % least 3 month prior screen ) . Have take medication low blood sugar insulin glargine , pioglitazone , metformin 3 month enter study 1week period , within 1 week enter study . Have one episode major ( severe ) hypoglycemia 6 month enter study . Are pregnant intend become pregnant study sexually active woman actively practice birth control . Women breastfeed . Have significant disease blood , heart , kidney , gastrointestinal system , significant disease cancer . Have kidney transplant currently kidney dialysis . Have cancer 's never treat , 's currently treat , diagnose within last 5 year . Have bad reaction exenatide past condition recommend exposed exenatide exenatide 's ingredient . Have use drug weight loss 3 month enter study 1week period , within 1 month enter study . Are currently weightloss program one within 3 month enter study . Have blood transfusion severe blood loss within 3 month enter study . Are take systemic glucocorticoid receive systemic glucocorticoid within 8 week enter study . Have irregular sleep cycle ( example , sleep day work night ) . Have history pancreatitis . Have receive treatment experimental drug within 30 day enter study . If metformin , condition recommend exposed metformin , condition associate hypoperfusion , hypoxemia , dehydration , sepsis . If metformin , radiologic contrast study perform within 48 hour enter study . If pioglitazone , condition recommend exposed pioglitazone , include congestive heart failure , take pioglitazone dose approve use insulin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>metformin</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>insulin glargine</keyword>
</DOC>